{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:04Z","timestamp":1786991224840,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jacbts.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T18:28:11Z","timestamp":1561400891000},"page":"438-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Emerging Therapeutics for the Treatment\u00a0of Light Chain and Transthyretin Amyloidosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Kathleen W.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith E.","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib2","first-page":"1","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"44","author":"Gillmore","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2019.02.002_bib5","first-page":"113","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib8","first-page":"1","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacbts.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1634\/theoncologist.11-7-824","article-title":"Primary (AL) amyloidosis in plasma cell disorders","volume":"11","author":"Muller","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.jacbts.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.1998.01034.x","article-title":"Chromosomal abnormalities in systemic amyloidosis","volume":"103","author":"Fonseca","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1365-2141.2000.02488.x","article-title":"Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13","volume":"111","author":"Avet-Loiseau","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0002-9440(10)64115-6","article-title":"Translocation t(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis","volume":"158","author":"Perfetti","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2141.2002.03438.x","article-title":"Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis","volume":"117","author":"Harrison","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2004-04-1424","article-title":"Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis","volume":"105","author":"Abraham","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00380-015-0658-0","article-title":"Late gadolinium enhancement in cardiac amyloidosis: attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia","volume":"31","author":"Hashimura","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacbts.2019.02.002_bib22","first-page":"193","article-title":"Amyloidosis and the heart","volume":"2","author":"Dubrey","year":"1995","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacbts.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A\u00a0phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1249543","article-title":"How thalidomide works against cancer","volume":"343","author":"Stewart","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2010-07-295485","article-title":"Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis","volume":"116","author":"Sanchorawala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/17425255.2013.827169","article-title":"Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma","volume":"9","author":"Gay","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib34","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19\u202f: a lipid raft \u2014 dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib36","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/cam4.725","article-title":"Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis","volume":"5","author":"Lisenko","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib40","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib41","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacbts.2019.02.002_bib42","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A\u00a0phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib43","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jacbts.2019.02.002_bib44","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacbts.2019.02.002_bib45","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2019.02.002_bib48","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jacbts.2019.02.002_bib50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jacbts.2019.02.002_bib51","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib52","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib53","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1523-1755.2005.00571.x","article-title":"Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage","volume":"68","author":"Keeling","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacbts.2019.02.002_bib54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacbts.2019.02.002_bib55","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jacbts.2019.02.002_bib57","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib58","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2019.02.002_bib59","article-title":"Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib60","first-page":"B14","article-title":"Cardiac response to chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis with global longitudinal strain: results from the phase 1b trial","volume":"31","author":"Shames","year":"2018","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"suppl 1","key":"10.1016\/j.jacbts.2019.02.002_bib61","first-page":"1834","article-title":"Preliminary pharmacokinetic study of a bispecific peptide for pretargeting immunotherapy of amyloidosis using PreClinical SPECT\/CT","volume":"59","author":"Stuckey","year":"2018","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2011.00032","article-title":"Generation and characterization of anti-AA amyloid-specific monoclonal antibodies","volume":"2","author":"Wall","year":"2011","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib63","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","article-title":"2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis","volume":"23","author":"Renz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jacbts.2019.02.002_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacbts.2019.02.002_bib65","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib66","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-07-865857","article-title":"Beyond NEOD001 for systemic light-chain amyloidosis","volume":"132","author":"Varga","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib67","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2019.02.002_bib68","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/PL00000791","article-title":"Transthyretin: a review from a structural perspective","volume":"58","author":"Hamilton","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jacbts.2019.02.002_bib69","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/74082","article-title":"Rational design of potent human transthyretin amyloid disease inhibitors","volume":"7","author":"Klabunde","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib70","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in\u00a0vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.jacbts.2019.02.002_bib71","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.jacbts.2019.02.002_bib72","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 4","key":"10.1016\/j.jacbts.2019.02.002_bib73","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2019.02.002_bib74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00019052-199610000-00007","article-title":"Familial amyloid polyneuropathy: new developments in genetics and treatment","volume":"9","author":"Coelho","year":"1996","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmg.31.5.351","article-title":"Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate","volume":"31","author":"Holmgren","year":"1994","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacbts.2019.02.002_bib76","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jacbts.2019.02.002_bib77","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1073\/pnas.95.22.12956","article-title":"Inhibiting transthyretin conformational changes that lead to amyloid fibril formation","volume":"95","author":"Peterson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2019.02.002_bib78","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"1","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.jacbts.2019.02.002_bib79","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2019.02.002_bib80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Hear Fail"},{"key":"10.1016\/j.jacbts.2019.02.002_bib81","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2019.02.002_bib82","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib83","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib84","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2019.02.002_bib85","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacbts.2019.02.002_bib86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jacbts.2019.02.002_bib89","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2019.02.002_bib90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib91","first-page":"407","article-title":"Active nuclear import of single-stranded oligonucleotides and their complexes with non-karyophilic macromolecules","volume":"90","author":"Hartig","year":"1998","journal-title":"Biol Cell"},{"key":"10.1016\/j.jacbts.2019.02.002_bib92","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/nar\/28.2.582","article-title":"Nucleocytoplasmic shuttling: a novel in\u00a0vivo property of antisense phosphorothioate oligodeoxynucleotides","volume":"28","author":"Lorenz","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2019.02.002_bib93","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacbts.2019.02.002_bib94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib95","series-title":"Molecular Medical Microbiology (Second Edition) Vol. 1","first-page":"449","article-title":"Pattern Recognition Receptors and the Innate Immune Network","author":"Wade","year":"2015"},{"key":"10.1016\/j.jacbts.2019.02.002_bib96","first-page":"284","article-title":"Binding of serum amyloid P-component (SAP) by amyloid fibrils","volume":"38","author":"Pepys","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib97","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nm0897-855","article-title":"Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene","volume":"3","author":"Botto","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2019.02.002_bib99","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2019.02.002_bib100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2017.1370421","article-title":"Attitudes about when and how to treat patients with AL amyloidosis: an international survey","volume":"24","author":"Milani","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jacbts.2019.02.002_bib101","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib102","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood.V116.21.3021.3021","article-title":"Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis","volume":"116","author":"Tapan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib103","doi-asserted-by":"crossref","first-page":"E212","DOI":"10.1002\/ajh.24176","article-title":"Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis","volume":"90","author":"Hussain","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacbts.2019.02.002_bib104","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/blood.V128.22.4511.4511","article-title":"Challenges of using NT-Probnp for response assessment in systemic AL amyloidosis \u2014 analysis of a prospective study","volume":"128","author":"Wechalekar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2019.02.002_bib105","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcmg.2016.04.008","article-title":"Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system","volume":"10","author":"Barros-Gomes","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacbts.2019.02.002_bib106","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacbts.2019.02.002_bib107","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.14585","article-title":"The six-minute walk test is a valuable measure of functional change following chemotherapy for AL (light-chain) cardiac amyloidosis","volume":"177","author":"Decker","year":"2017","journal-title":"Br J Haematol"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X19300567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X19300567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:21:23Z","timestamp":1762820483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X19300567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2452302X19300567"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2019.02.002","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapeutics for the Treatment\u00a0of Light Chain and Transthyretin Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}